NovoCure Limited - Ordinary Shares (NVCR) earnings
NVCR earnings moved a median of -0.27% by the close. Quarterly and annual NVCR reports and results, each read against the price at its own news timestamp. Back to the NVCR overview →
33 measured NVCR earnings events.
Where these NVCR earnings landedvs 33 measured NVCR earnings reactions
| Middle 50% of NVCR earnings reactions | -4.42% to +3.77% |
|---|---|
| Median reaction (to close) | -0.27% |
| Measured reactions | 33 |
Point-in-time · zero look-ahead
Half of the 33 NVCR earnings events with a measured close landed between -4.42% and +3.77%; 48% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Novocure to Report Third Quarter 2026 Financial Results | Press release | +2.69% | +0.70% | |
| Form 10-Q NovoCure Ltd For: Jun 30 | SEC filing · Form 10-Q | +11.11% | +11.06% | |
| Novocure Reports Second Quarter 2026 Financial Results | Press release | +11.11% | +11.06% | |
| Novocure to Report Second Quarter 2026 Financial Results | Press release | +0.00% | +2.60% | |
| Form 10-Q NovoCure Ltd For: Mar 31 | SEC filing · Form 10-Q | +7.81% | +14.36% | |
| Novocure Reports First Quarter 2026 Financial Results | Press release | +7.81% | +14.36% | |
| Novocure to Report First Quarter 2026 Financial Results | Press release | +1.09% | -1.72% | |
| Form 10-K NovoCure Ltd For: Dec 31 | SEC filing · Form 10-K | +0.38% | +3.77% | |
| Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update | Press release | -3.86% | -5.66% | |
| Form 10-Q NovoCure Ltd For: Sep 30 | SEC filing · Form 10-Q | -1.37% | -4.90% | |
| Novocure Reports Third Quarter 2025 Financial Results | Press release | -1.37% | -4.90% | |
| Novocure to Report Third Quarter 2025 Financial Results | Press release | +2.63% | +8.04% | |
| Form 10-Q NovoCure Ltd For: Jun 30 | SEC filing · Form 10-Q | -10.18% | -24.00% | |
| Novocure Reports Second Quarter 2025 Financial Results | Press release | -10.18% | -24.00% | |
| Novocure to Report Second Quarter 2025 Financial Results | Press release | +0.61% | -1.17% | |
| Form 10-Q NovoCure Ltd For: Mar 31 | SEC filing · Form 10-Q | -2.72% | -2.06% | |
| Novocure Reports First Quarter 2025 Financial Results | Press release | -2.72% | -2.06% | |
| Novocure to Report First Quarter 2025 Financial Results | Press release | -0.89% | -1.74% | |
| Form 10-K NovoCure Ltd For: Dec 31 | SEC filing · Form 10-K | -3.13% | -4.42% | |
| Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update | Press release | +0.58% | -0.27% | |
| Form 10-Q NovoCure Ltd For: Sep 30 | SEC filing · Form 10-Q | -4.88% | +2.29% | |
| Novocure Reports Third Quarter 2024 Financial Results | Press release | -4.88% | +2.29% | |
| Novocure to Report Third Quarter 2024 Financial Results | Press release | -0.13% | -2.87% | |
| Form 10-Q NovoCure Ltd For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +0.32% | |
| Novocure Reports Second Quarter 2024 Financial Results | Press release | +0.00% | +0.32% | |
| Novocure to Report Second Quarter 2024 Financial Results | Press release | -0.90% | +0.46% | |
| Form 10-Q NovoCure Ltd For: Mar 31 | SEC filing · Form 10-Q | -4.78% | +5.97% | |
| Novocure Reports First Quarter 2024 Financial Results | Press release | -4.78% | +5.97% | |
| Novocure to Report First Quarter 2024 Financial Results | Press release | -1.41% | -0.90% | |
| Form 10-K NovoCure Ltd For: Dec 31 | SEC filing · Form 10-K | -7.83% | -10.25% | |
| Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update | Press release | +2.02% | +10.86% | |
| Form 10-Q NovoCure Ltd For: Sep 30 | SEC filing · Form 10-Q | -5.39% | -10.08% | |
| Novocure Reports Third Quarter 2023 Financial Results | Press release | -5.39% | -10.08% |
Keep exploring
More NVCR: analyst actions → · SEC filings → · NVCR overview →